ReEngage Therapeutics, Inc.
ReEngage Therapeutics, Inc., is a clinical stage oncology company focused on developing novel treatments for longevity-related diseases, including neurodegeneration and cancer. The company is developing a de-risked molecule, MTB-9655, to treat 3rd line metastatic colorectal cancer.